GlassScriptPhysician profile
Katie E Uram
NPI 1396023099
$3,636.78
in general payments reported to CMS, 2019-2025
30 companies · $827 in 2025
The $827 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $869 · 2022: $711 · 2023: $648 · 2024: $581 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,048 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.03 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $681.74 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $577.58 | 2021-2025 | |
| Abbvie INC. | $362.37 | 2021-2025 | |
| Glaxosmithkline, LLC. | $294.16 | 2021-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $279.29 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.26 | 2021-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Genzyme Corporation | $200.69 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $142.30 | 2021-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Amgen INC. | $134.98 | 2021-2025 | Prolia, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $111.81 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lundbeck LLC | $83.94 | 2025 | Rexulti |
| Abbott Laboratories | $65.03 | 2021-2022 | |
| Amarin Pharma, INC. | $50.05 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $48.18 | 2021-2023 | Livalo |
| Esperion Therapeutics, INC. | $41.94 | 2021-2025 | Nexletol |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $39.01 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $38.75 | 2021-2023 | Spravato |
| Astellas Pharma US INC | $32.74 | 2023-2025 | Veozah |
| Sanofi Pasteur INC. | $30.57 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.15 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.50 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $22.45 | 2023 | Rexulti |
| Exact Sciences Corporation | $21.67 | 2023 | Cologuard Collection Kit |
| Vivus LLC | $21.07 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.05 | 2025 | Voquezna |
| Dexcom, INC. | $17.48 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $16.24 | 2023 | Accrufer |
| Axsome Therapeutics, INC. | $15.68 | 2025 | Auvelity |
| Arbor Pharmaceuticals, INC. | $15.38 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Uram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.